'The Interview': Jennifer Lawrence Regrets Everything She’s Ever Said or Done
'The Interview': Jennifer Lawrence Regrets Everything She’s Ever Said or Done
189 days agoThe DailyThe New York Times
Podcast36 min 22 sec
Listen to Episode
Note: AI-generated summary based on third-party content. Not financial advice. Read more.
Quick Insights

A recent celebrity endorsement for the postpartum depression drug Zerzovay could create a near-term catalyst for its developers, Sage Therapeutics (SAGE) and Biogen (BIIB). This organic, high-profile mention may significantly boost public awareness and drive initial sales for the new treatment. For long-term investors, the value of strong intellectual property in media remains a key theme. Companies like Lionsgate (LGF.A) with The Hunger Games and Disney (DIS) with its Marvel franchises demonstrate the power of repeatable content. Consider these media giants for their durable IP-driven revenue streams.

Detailed Analysis

Zerzovay (Sage Therapeutics - SAGE / Biogen - BIIB)

  • Actress Jennifer Lawrence mentioned her personal experience with postpartum depression and stated she took a new drug called Zerzovay.
  • She described her experience with the drug in very positive terms, saying, "I took it for two weeks, and it really helped me."
  • She explicitly noted that this was not a paid endorsement, which can make the testimonial feel more authentic to the public.

Takeaways

  • This high-profile, organic celebrity endorsement could significantly boost public awareness and positive sentiment for Zerzovay, a treatment for postpartum depression.
  • Positive patient stories, especially from trusted public figures, can be a powerful driver for a new drug's adoption.
  • Investors interested in the pharmaceutical and biotech sectors might view this as a positive indicator for the market potential of Zerzovay. The companies behind the drug are Sage Therapeutics (SAGE) and its partner Biogen (BIIB).

Art (Alternative Investment)

  • Jennifer Lawrence mentioned that during her break from acting, she began to learn about contemporary post-war art.
  • This interest was sparked by her husband, who is an art dealer.

Takeaways

  • This serves as a reminder of alternative asset classes beyond traditional stocks and cryptocurrencies.
  • Fine art, particularly in specific categories like contemporary post-war art, can be a component of a diversified investment portfolio, especially for individuals with a high net worth.
  • Investing in art is a specialized field that often requires expert guidance (like that of an art dealer) and may be less liquid than public markets.

Film Franchises (Lionsgate / Disney)

  • The discussion highlighted Jennifer Lawrence's early career, which was built on starring roles in two major film franchises: The Hunger Games and X-Men.

Takeaways

  • This reinforces the core investment thesis for many major media companies: the immense value of strong, repeatable intellectual property (IP).
  • Successful franchises generate revenue for years through sequels, merchandise, and streaming rights.
    • The Hunger Games remains a cornerstone asset for its studio, Lionsgate (LGF.A, LGF.B).
    • The X-Men property is a key part of the valuable Marvel universe, owned by The Walt Disney Company (DIS).
  • When evaluating media stocks, investors should pay close attention to the strength and future pipeline of a company's film and television franchises.
Ask about this postAnswers are grounded in this post's content.
Episode Description
At only 35, the actress has been through the celebrity wringer. Here’s where she landed. Thoughts? Email us at theinterview@nytimes.com Watch our show on YouTube: youtube.com/@TheInterviewPodcast For transcripts and more, visit: nytimes.com/theinterview Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app.
About The Daily
The Daily

The Daily

By The New York Times

This is what the news should sound like. The biggest stories of our time, told by the best journalists in the world. Hosted by Michael Barbaro, Rachel Abrams and Natalie Kitroeff. Twenty minutes a day, five days a week, ready by 6 a.m. Unlock full access to New York Times podcasts and explore everything from politics to pop culture. Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. Listen to this podcast in New York Times Audio, our new iOS app for news subscribers. Download now at nytimes.com/audioapp